Cardiovascular Drugs and Therapy

, Volume 28, Issue 3, pp 273–279

Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: Randomised Comparison of Bivalirudin Versus Unfractionated Heparin in Patients at High Risk of Bleeding Undergoing Elective Coronary Stenting Throught The Femoral Approach. Rationale and Design

  • Carlo Briguori
  • Gabriella Visconti
  • Amelia Focaccio
  • Michael Donahue
  • Bruno Golia
  • Lucio Selvetella
  • Bruno Ricciarelli
ORIGINAL ARTICLE

Abstract

Purpose

Bivalirudin (Angiox, The Medicine’s Company, Parsippany, NJ), a synthetic direct thrombin inhibitor, when compared with standard antithrombotic therapy (including unfractionated heparin [UFH] alone or plus a glycoprotein IIb/IIIa inhibitor) determines a significant decrease of major and minor bleeding and similar protection against ischemic events both in elective and in urgent percutaneous coronary intervention (PCI). There is a lack of prospective clinical trial assessing the safety and the efficacy of bivalirudin compared with UFH alone in the subset of biomarker negative patients at high risk of bleeding undergoing to elective PCI through the femoral approach.

Methods

This is a single-center, investigator-driven, randomized, double-blind, controlled trial (www.clinicaltrial.gov registration: NCT01465503). Consecutive patients at high bleeding risk (score ≥10 according to Nikolsky et al.) undergoing elective PCI through the femoral approach will be screened for eligibility. Included patients will be randomized (ratio 1.1) to bivalirudin (Bivalirudin group) and UFH (UFH group). The primary endpoint will be the rate of major bleeding (REPLACE 2 criteria). We expect a major bleeding rate ≥5 % in the UFH group versus a ≤3 % event rate in the Bivalirudin group. Aiming for a 0.05 alpha and 0.80 power, a total of 662 patients will be needed. This number will be increased by about 25 % (leading to a total of ≈830 patients) because of uncertainty about expected endpoint rates.

Conclusions

The present trial will give important information on what is the best anticoagulation regimen when performing PCI through the femoral approach in patients at high risk for bleeding.

Keywords

Percutaneous coronary intervention Unfractionated heparin Bivalirudin Bleeding Outcome 

References

  1. 1.
    Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 accf/aha/scai guideline for percutaneous coronary intervention. A report of the american college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol. 2011;58:e44–e122.PubMedCrossRefGoogle Scholar
  2. 2.
    Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008;51:690–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the global registry of acute coronary events (grace). Eur Heart J. 2003;24:1815–23.PubMedCrossRefGoogle Scholar
  4. 4.
    Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the replace-2 trial. Am J Cardiol. 2007;100:1364–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92:930–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the acuity trial. J Am Coll Cardiol. 2007;49:1362–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Rao SV, O’Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96:1200–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–76.PubMedCrossRefGoogle Scholar
  10. 10.
    Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (horizons-ami): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149–59.PubMedCrossRefGoogle Scholar
  11. 11.
    Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the acuity trial. JAMA. 2007;298:2497–506.PubMedCrossRefGoogle Scholar
  12. 12.
    Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al. Bivalirudin during primary pci in acute myocardial infarction. N Engl J Med. 2008;358:2218–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein iib/iiia blockade compared with heparin and planned glycoprotein iib/iiia blockade during percutaneous coronary intervention: Replace-2 randomized trial. JAMA. 2003;289:853–63.PubMedCrossRefGoogle Scholar
  14. 14.
    National Kidney Foundation. K/doqi clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266.Google Scholar
  15. 15.
    World Medical Association Inc. Declaration of helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc. 2009;107:403–5.Google Scholar
  16. 16.
    Anello C, O’Neill RT, Dubey S. Multicentre trials: a us regulatory perspective. Stat Methods Med Res. 2005;14:303–18.PubMedCrossRefGoogle Scholar
  17. 17.
    Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the consort pro extension. JAMA. 2013;309:814–22.PubMedCrossRefGoogle Scholar
  18. 18.
    Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, et al. Acute catheterization and urgent intervention triage strategy (acuity) trial: study design and rationale. Am Heart J. 2004;148:764–75.PubMedCrossRefGoogle Scholar
  19. 19.
    Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.PubMedCrossRefGoogle Scholar
  21. 21.
    Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J. 2007;28:1936–45.PubMedCrossRefGoogle Scholar
  22. 22.
    Rao SV, McCoy LA, Spertus JA, Krone RJ, Singh M, Fitzgerald S, et al. An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the national cardiovascular data registry cathpci registry. JACC Cardiovasc Interv. 2013;6:897–904.PubMedCrossRefGoogle Scholar
  23. 23.
    Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:688–96.PubMedCrossRefGoogle Scholar
  24. 24.
    Tarantini G, Brener SJ, Barioli A, Gratta A, Parodi G, Rossini R, et al. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials. Am Heart J. 2014;167:401–12. e406.PubMedCrossRefGoogle Scholar
  25. 25.
    Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog angioplasty study investigators. N Engl J Med. 1995;333:764–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Graham MM, Ghali WA, Faris PD, Galbraith PD, Norris CM, Knudtson ML. Survival after coronary revascularization in the elderly. Circulation. 2002;105:2378–84.PubMedCrossRefGoogle Scholar
  27. 27.
    Robertson T, Kennard ED, Mehta S, Popma JJ, Carrozza Jr JP, King 3rd SB, et al. Influence of gender on in-hospital clinical and angiographic outcomes and on one-year follow-up in the new approaches to coronary intervention (naci) registry. Am J Cardiol. 1997;80:26K–39K.PubMedCrossRefGoogle Scholar
  28. 28.
    Cox N, Resnic FS, Popma JJ, Simon DI, Eisenhauer AC, Rogers C. Comparison of the risk of vascular complications associated with femoral and radial access coronary catheterization procedures in obese versus nonobese patients. Am J Cardiol. 2004;94:1174–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein iib/iiia inhibitors: the do tirofiban and reopro give similar efficacy outcome (target) trial. Am Heart J. 2005;149:869–75.PubMedCrossRefGoogle Scholar
  30. 30.
    Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the national cardiovascular data registry. Circ Cardiovasc Interv. 2009;2:222–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010;31:2501–55.PubMedCrossRefGoogle Scholar
  32. 32.
    Sobel M, Fish WR, Toma N, Luo S, Bird K, Mori K, et al. Heparin modulates integrin function in human platelets. J Vasc Surg. 2001;33:587–94.PubMedCrossRefGoogle Scholar
  33. 33.
    Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 1992;67:639–43.PubMedGoogle Scholar
  34. 34.
    Schulz S, Mehilli J, Ndrepepa G, Neumann FJ, Birkmeier KA, Kufner S, et al. Bivalirudin vs. Unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the isar-react 3 trial. Eur Heart J. 2010;31:582–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Rao SV, O’Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47:809–16.PubMedCrossRefGoogle Scholar
  36. 36.
    Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736–47.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Carlo Briguori
    • 1
    • 3
  • Gabriella Visconti
    • 1
  • Amelia Focaccio
    • 1
  • Michael Donahue
    • 1
  • Bruno Golia
    • 1
  • Lucio Selvetella
    • 2
  • Bruno Ricciarelli
    • 1
  1. 1.Department of CardiologyClinica MediterraneaNaplesItaly
  2. 2.Department of Vascular SurgeryClinica MediterraneaNaplesItaly
  3. 3.Laboratory of Interventional CardiologyClinica MediterraneaNaplesItaly

Personalised recommendations